$340 Million is the total value of Ally Bridge Group (NY) LLC's 31 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPDR SER TRput | $25,142,000 | -7.2% | 200,000 | 0.0% | 7.39% | +9.9% | ||
| MRTX | MIRATI THERAPEUTICS INC | $16,806,000 | +9.5% | 95,000 | 0.0% | 4.94% | +29.6% | |
| FATE | FATE THERAPEUTICS INC | $16,003,000 | -31.7% | 270,000 | 0.0% | 4.70% | -19.2% | |
| SYRS | SYROS PHARMACEUTICALS INC | $15,376,000 | -18.0% | 3,439,895 | 0.0% | 4.52% | -2.9% | |
| GOSS | GOSSAMER BIO INC | $14,770,000 | +54.8% | 1,175,000 | 0.0% | 4.34% | +83.2% | |
| COGT | COGENT BIOSCIENCES INC | $13,646,000 | +3.7% | 1,622,591 | 0.0% | 4.01% | +22.7% | |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $10,036,000 | -5.2% | 406,986 | 0.0% | 2.95% | +12.2% | |
| APELLIS PHARMACEUTICALS INCcall | $9,888,000 | -47.8% | 300,000 | 0.0% | 2.91% | -38.3% | ||
| NAUT | NAUTILUS BIOTECHNOLOGY INC | $9,210,000 | -39.2% | 1,500,000 | 0.0% | 2.71% | -28.1% | |
| NSTG | NANOSTRING TECHNOLOGIES INC | $8,882,000 | -25.9% | 185,000 | 0.0% | 2.61% | -12.3% | |
| MDVL | MEDAVAIL HOLDINGS INC | $8,529,000 | -76.2% | 2,920,780 | 0.0% | 2.51% | -71.8% | |
| ACET | ADICET BIO INC | $3,332,000 | -23.8% | 425,000 | 0.0% | 0.98% | -9.8% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDAVAIL HOLDINGS INC | 11 | Q2 2023 | 8.9% |
| UNUM THERAPEUTICS INC | 8 | Q3 2022 | 7.3% |
| RAPID MICRO BIOSYSTEMS INC-A | 8 | Q2 2023 | 3.5% |
| FATE THERAPEUTICS INC | 7 | Q2 2022 | 5.8% |
| VIRIDIAN THERAPEUTICS INC | 7 | Q2 2023 | 6.8% |
| SYROS PHARMACEUTICALS INC | 7 | Q2 2022 | 4.9% |
| REPLIGEN CORP | 7 | Q4 2022 | 6.5% |
| NAUTILUS BIOTECHNOLOGY INC | 7 | Q4 2022 | 3.8% |
| ARVINAS INC | 6 | Q1 2022 | 7.5% |
| NUVATION BIO INC | 6 | Q2 2022 | 4.9% |
View Ally Bridge Group (NY) LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | November 19, 2020 | 1,420,500 | 8.0% |
View Ally Bridge Group (NY) LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Ally Bridge Group (NY) LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.